Intuitive Surgical, Inc. (ISRG)
| Market Cap | 154.74B -3.2% |
| Revenue (ttm) | 11.58B +20.5% |
| Net Income | 2.96B +7.7% |
| EPS | 8.27 +9.5% |
| Shares Out | 353.28M |
| PE Ratio | 52.94 |
| Forward PE | 37.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,597,153 |
| Open | 433.50 |
| Previous Close | 433.18 |
| Day's Range | 432.00 - 440.40 |
| 52-Week Range | 328.57 - 603.88 |
| Beta | 1.46 |
| Analysts | Buy |
| Price Target | 478.53 (+9.25%) |
| Earnings Date | Oct 20, 2026 |
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling,... [Read more]
Financial Performance
In 2025, Intuitive Surgical's revenue was $10.06 billion, an increase of 20.51% compared to the previous year's $8.35 billion. Earnings were $2.86 billion, an increase of 22.97%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for ISRG stock is "Buy." The 12-month stock price target is $478.53, which is an increase of 9.25% from the latest price.
News
Intuitive Surgical says in China, the operating environment remains challenging
Says continued to see increasing segmentation across our customer base. Says as of Q3, nearly 4,000 international customers have a Da Vinci program, and nearly 25% operate two or more…
Intuitive Surgical Stock Slides Despite Earnings Beat as Company Discloses Settlement
Intuitive Surgical beat quarterly estimates but disclosed an antitrust settlement and narrowed its procedure-growth forecast.
Intuitive Surgical announces $450M antitrust litigation settlement agreement
Following a mediation in the “In re: da Vinci Surgical Robot Antitrust Litigation” class action, the company reached written agreement, without any admission of liability or wrongdoing, to settle the…
Intuitive Surgical Earnings Call Transcript: Q3 2026
Q3 revenue rose 22% and procedures grew 15%, supported by broad system placements and growth across da Vinci and Ion. FY2026 da Vinci procedure growth guidance narrowed to 14%-15%; upcoming pricing actions are expected to reduce I&A revenue per procedure 3%-5% at constant mix once fully implemented.
Intuitive Surgical Earnings release: Q3 2026
Intuitive Surgical released its Q3 2026 earnings on October 20, 2026, summarizing the period's financial results.
Intuitive Surgical reports Q3 EPS $3.00, consensus $2.64
Reports Q3 revenue $3.05B, consensus $2.91B. Worldwide procedures grew approximately 15% compared with the third quarter of 2025. Da Vinci procedures grew approximately 14%, and Ion procedures grew ap...
Intuitive Surgical narrows FY26 da Vinci procedure growth view to 14%-15%
Previous view was 13.5%-15.5%. Raises FY26 gross profit margin view to 68.7%-69.3% from 68%-69%. Backs FY26 operating expense growth view 11%-13%. The company said, “The range for expected non-GAAP gr...
Intuitive Announces Third Quarter Earnings
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today ...
Intuitive Surgical price target raised to $415 from $400 at Mizuho
Mizuho raised the firm’s price target on Intuitive Surgical (ISRG) to $415 from $400 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices…
Intuitive Surgical price target lowered to $454 from $469 at BTIG
BTIG lowered the firm’s price target on Intuitive Surgical (ISRG) to $454 from $469 and keeps a Buy rating on the shares as part of a broader research note previewing…
Intuitive Surgical initiated with an Overweight at Barclays
Barclays initiated coverage of Intuitive Surgical (ISRG) with an Overweight rating and $485 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
3 Healthcare Stocks with More Than 20% Upside and Recent Buy Ratings
Eli Lilly ($LLY), UnitedHealth Group ($UNH), and Intuitive Surgical ($ISRG) have each received Buy ratings from Wall Street analysts on September 14. Based on their average analyst price targets, the…
Intuitive Surgical Transcript: Wells Fargo 21st Annual Healthcare Conference
Global procedure growth remains a priority, with innovation and new programs like Extended Use Instruments aimed at stimulating growth, especially in cost-sensitive markets. Capital equipment placements are strong, competition is intensifying, and AI-driven digital offerings are gaining traction. Financial performance is robust, exceeding long-term averages.
New meta-analysis shows statistically significant improvements in patient outcomes associated with da Vinci surgery versus laparoscopic and open surgery across 13 common benign conditions
Largest comparative meta-analysis of its kind found da Vinci robotic-assisted surgery was associated with shorter hospital stays and a faster return to work compared with laparoscopic and open surgery...
Intuitive Surgical upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform.
Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition
Oppenheimer upgraded Intuitive Surgical (ISRG) to Outperform from Perform with a $500 price target. Field checks suggest workflow challenges for Johnson & Johnson’s (JNJ) Ottava that limit long-term a...
Intuitive Collaborates with Deion “Coach Prime” Sanders to Raise Patient Awareness of Surgical Options
Intuitive today announced a collaboration with Deion “Coach Prime” Sanders to help increase patient awareness and understanding of surgical options.
Intuitive Shares Vision for an AI-Enabled Future of Healthcare
SUNNYVALE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, will outline its visio...
Why Intuitive Surgical Stock Plunged Today
Intuitive Surgical (ISRG) shares plummeted Friday after the maker of robotic surgical tools failed to raise the outlook for its flagship product despite better-than-expected second-quarter results.
Friday's Morning Movers: SPCX Scrubs Test Flights, AAPL Upgrade, ISRG Earnings
Diane King Hall discusses Intuitive Surgical (ISRG) earnings, explaining how GLP-1 trends have hit the company. She also talks about SpaceX (SPCX) shares coming back to Earth after scrubbing Starship'...
Intuitive Surgical falls as Obamacare concerns rekindle medtech demand debate
Intuitive Surgical shares fell more than 12% before the bell on Friday after it maintained its global growth forecast for procedures performed with its da Vinci surgical robots and warned that change...
Intuitive Surgical stock sinks despite earnings beat on 2026 procedure growth outlook
Shares of Intuitive Surgical tumbled about 12% in premarket trading on Friday after the robotic surgery company issued a full-year procedure growth outlook that fell short of investor expectations, ov...
Intuitive Surgical beats quarterly estimates on strong demand for its robotic systems
Intuitive Surgical on Thursday maintained its 2026 forecast for worldwide growth in procedures assisted by its cutting-edge da Vinci robots, after beating Wall Street estimates for second-quarter pr...
Intuitive Surgical Earnings Call Transcript: Q2 2026
Q2 delivered strong revenue and procedure growth, driven by robust adoption of da Vinci 5, SP, and Ion platforms. Guidance for 2026 remains positive, with continued innovation, stable capital demand, and expanding access in cost-sensitive markets.